Evidence map›Paper›PMID 39046566›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024

Emergence of a novel FRI-type carbapenemase; blaFRI-12 in Enterobacter asburiae located on an IncR plasmid.

Laura F Mataseje, Florence Doualla-Bell, Ken Fakharuddin, Simon Wong, Ariane Yechouron

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Carbapenemase-producing hypervirulentJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura F MatasejeNational Microbiology Laboratory, Winnipeg, MB, R3E 3R2, Canada. Laura.mataseje@phac-aspc.gc.ca.
Florence Doualla-BellLaboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, Québec, Canada.
Ken FakharuddinNational Microbiology Laboratory, Winnipeg, MB, R3E 3R2, Canada.
Simon WongLaboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, Québec, Canada.
Ariane YechouronDépartement clinique de médecine de laboratoire, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-resistance in Enterobacter spp due to acquisition of mobile carbapenemases is of concern. An Enterobacter spp grew on ChromID CARBA medium and was positive for the mCIM carbapenemase detection assay. Susceptibility testing showed resistance to aztreonam and reduced susceptibility to imipenem. Conventional PCR using FRI primers detected a bla

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesEnterobacterEnterobacteriaceae InfectionsHumansMicrobial Sensitivity TestsPlasmidsWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasescarbapenemase

Identifiers

PMID39046566
PMCPMC11405460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.